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3-O-(3′,3′-dimethylsuccinyl) betulinic acid, also termed PA-457 or DSB, is a novel HIV-1 inhibitor that blocks virus maturation by disrupting
cleavage of the capsid precursor, CA-SP1. To better define the molecular target for PA-457, we prepared a panel of mutant viruses with point
deletions spanning the CA-SP1 cleavage domain and characterized each of these viruses for PA-457 sensitivity. Our results indicate that amino
acid residues in the N-terminal half of SP1 serve as determinants of PA-457 activity, while residues in the C-terminal half of SP1 were not
involved in compound activity. These findings support and extend previous observations that PA-457 is a specific inhibitor of CA-SP1 cleavage
and identify the CA-SP1 domain as the primary viral determinant for this novel inhibitor of HIV-1 replication.
© 2006 Elsevier Inc. All rights reserved.Keywords: PA-457; HIV; Maturation inhibitor; CA-SP1 cleavage; Viral determinantsIntroduction
HIV-1 assembly is driven largely by the Gag precursor
protein Pr55Gag. Following synthesis, Pr55Gag is transported to
the plasma membrane where virus assembly occurs (Freed,
1998; Morita and Sundquist, 2004; Swanstrom and Wills,
1997). Through a complex combination of Gag–lipid, Gag–
Gag, and Gag–RNA interactions, a multimeric budding
structure forms at the inner leaflet of the plasma membrane.
The budding virus particle is ultimately released from the cell
surface in a process that is promoted by an interaction between
the late domain in the p6 region of Gag (Gottlinger et al., 1991;
Huang et al., 1995) and host proteins, most notably TSG101 and
other cellular factors (Demirov et al., 2002a; Garrus et al., 2001;
Martin-Serrano et al., 2001; VerPlank et al., 2001).⁎ Corresponding author. 19008 Oxcart Place, Gaithersburg, MD 20886, USA.
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doi:10.1016/j.virol.2006.07.023Concomitant with particle release, the viral protease (PR)
cleaves both Pr55Gag and Pr160GagPol to generate the mature
Gag proteins matrix (MA), capsid (CA), nucleocapsid (NC),
and p6, two small Gag spacer peptides (SP1 and SP2), and the
mature pol-encoded enzymes PR, reverse transcriptase (RT),
and integrase (IN). Gag and GagPol cleavage triggers a
structural rearrangement termed maturation, during which the
immature particle transitions to a mature infectious viral particle
characterized by an electron-dense, conical core. The efficien-
cies with which PR cleaves its target sequences vary widely,
resulting in a highly ordered Gag and GagPol processing
cascade (Erickson-Viitanen et al., 1989; Kräusslich et al., 1988;
Mervis et al., 1988).
The sequential nature of Gag processing can be disrupted by
altering the amino acid sequence at cleavage sites within Gag
(Krausslich et al., 1995; Wiegers et al., 1998) and even partial
inhibition of Gag processing profoundly impairs virus matura-
tion and infectivity (Kaplan et al., 1993). Mutating key residues
in the p6 late domain (Demirov et al., 2002b; Gottlinger et al.,
1991; Huang et al., 1995) or inhibiting the interaction between
p6 and TSG101 (Demirov et al., 2002a; Garrus et al., 2001) also
delays Gag processing, and increases levels of the Gag cleavage
Fig. 1. A schematic representation of the Gag protein and the CA-SP1 boundary
sequences of the HIV-1 NL4-3 and point deletion mutants used in this study. The
sequences flanking the CA-SP1 cleavage site for HIV-1 NL4-3 are shown at the
top of the figure. Numbering the residues of CA-SP1 cleavage domain is based
on the standard nomenclature system for the Gag polyprotein of HXB2 virus
(Kuiken et al., 2000). A dashed line (-) represents residues that are identical to
the parent NL4-3, a delta (Δ) represents CA-SP1 cleavage domain residues that
are deleted in the point deletion mutants.
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been reported that deletions in the dimer initiation site (DIS) of
the viral genomic RNA lead to an accumulation of the capsid
precursor p25 and a defect in virus maturation (Liang et al.,
1998; Liang et al., 1999).
Recently, we and others reported on 3-O-(3′,3′-dimethyl-
succinyl) betulinic acid (PA-457), a potent HIV drug candidate
that employs a novel mechanism of action to block Gag
processing and inhibit virus replication (Li et al., 2003; Zhou et
al., 2004b). PA-457 potently inhibits replication of both
prototypic and clinical HIV-1 isolates and retains this antiviral
activity against viruses resistant to the three classes of approved
drugs targeting the viral enzymes RT and PR. Interestingly, the
compound is HIV-1 specific with no activity observed against
the related retroviruses HIV-2 or SIV. PA-457 inhibits virus
replication by specifically disrupting the conversion of the Gag
capsid precursor protein (p25CA-SP1) to mature capsid protein
(p24CA) resulting in the release of immature, non-infectious
virus particles. Using in vitro resistance selection experiments,
the determinants of PA-457 activity have been mapped to the
region flanking the CA-SP1 cleavage site (Li et al., 2003; Zhou
et al., 2004b).
In the current report, we further define the molecular
determinants of PA-457 activity. This work involved preparing
a comprehensive panel of single residue point deletion mutants
spanning the entire CA-SP1 boundary domain (GHKARVL-
AEAMSQVTNPATIM), and characterizing each of the non-
defective mutants with respect to infectivity, replication, Gag
processing and PA-457 sensitivity. The results reported here are
consistent with results from previously reported resistance
selection experiments that identified the first (A364) and third
(A366) residues of SP1 as critical to PA-457 activity (Li et al.,
2003; unpublished results). Significantly, the results of the
current study extend the earlier work and identify additional
SP1 residues involved in mediating the PA-457 antiviral effect.
Not unexpectedly, our data indicated that the Gag residues
associated with compound activity reside primarily in the N-
terminal domain of SP1. The results reported here demonstrate
that multiple SP1 residues serve as viral determinants of PA-457
activity and further support the hypothesis that the CA-SP1
cleavage domain serves as the primary viral determinant for this
potent inhibitor of HIV-1 replication.
Results
Effects of CA-SP1 point deletions on virus production and Gag
processing
To further define the molecular determinants of PA-457
activity, we generated a series of point deletions spanning the
CA-SP1 boundary region. This deletion-based mutagenesis
approach has been successfully used to characterize various
functional domains of retroviral Gag including MA, CA, NC,
and the late-assembly domain (Dorfman et al., 1994; Nelle and
Wills, 1996; Ott et al., 2005; Parent et al., 1995; Puffer et al.,
1997; Reil et al., 1998; Srinivasakumar et al., 1995; Xiang et al.,
1996; Yuan et al., 1999; Yuan et al., 2000). Mutant viruses withsingle residue point deletions spanning the Gag CA-SP1 cleav-
age domain (residues G357H358K359A360R361V362L363-A364E365-
A366M367S368Q369V370T371N372P373A374T375I376M377) were
generated in the context of the HIV-1 molecular clone NL4-3
(Fig. 1). As the Gag CA-SP1 region has been closely associated
with viral assembly and budding (Accola et al., 1998; Liang et
al., 2002), our initial efforts in characterizing these viruses
involved determining the effect of the point deletions on viral
particle production. HeLa cells were transfected in parallel with
DNA from the parental and variant NL4-3 proviral constructs.
Virus production was measured at 48 h post-transfection by p24
antigen capture. The results of these experiments demonstrated
that the majority of viruses containing point deletions within the
C-terminal domain of CA (ΔG357, ΔH358, ΔK359, ΔA360,
ΔR361 and ΔL363) or at the N-terminus of SP1 (ΔA364) were
defective for viral particle production (Fig. 2). For each of these
viruses, a two-log or greater reduction in virus production
relative to the parental NL4-3 was observed. Viral particle
production by capsid mutant ΔV362 was less affected, being
about 10% that of the parental NL4-3; however, this virus
exhibited a defect in CA-SP1 processing as evidenced by the
significant accumulation of virion-associated p25 by Western
blot (Fig. 3). It should be noted that cell-associated virus
expression of each of these point deletion variants was
comparable to the parental NL4-3 (unpublished results) and
the reduced level of particle production is apparently not due to
a reduction in Gag expression by the transfected cells. These
data demonstrate the importance of individual residues within
the C-terminal domain of CA and the single residue at the N-
terminus of SP1 to Gag processing and viral particle assembly
and release.
In contrast to these results, parallel transfections with SP1
point deletion-containing proviral DNA constructs (ΔE365,
Fig. 2. Analysis of virus production from HeLa cells transfected with the parental NL4-3 and single residue point deletion constructs spanning the CA-SP1 cleavage
domain. HeLa cells were transfected with equal amounts of the parental NL4-3 or single residue point deletion mutant proviral DNA. After 48 h, virions were pelleted
from the transfected culture supernatant and were analyzed for p24. The level of virus production by NL4-3 was set at 100%. Virus production for each point deletion
mutant was normalized by comparison with NL4-3. These data represent an average of at least four independent experiments. Experimental variability indicated by
standard deviation bars (gray).
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ΔA374, ΔT375, ΔI376 and ΔM377) produced significant
amounts of virus relative to the parental NL4-3 (Fig. 2). Virus
production by these mutants varied over a range of approxi-
mately 1 log and appeared to track as a function of the proximity
of the deletion to the CA-SP1 proteolytic cleavage site. For
example, SP1 mutants with deletions at residues proximal to the
cleavage site, E365, A366, and M367, were most affected, giving
<30% of the level of virus observed with the parental NL4-3.
This result is similar to those previously reported by Accola
et al. (1998) and Liang et al. (2002), and supports their
conclusion that the triple residue motif E365/A366/M367 within
the N-terminus of SP1 is critical to viral particle assembly and
budding.Fig. 3. Effect of point deletions (G357, H358, K359, A360, R361, V362, L363, or
A364) on production of extracellular virus. HeLa cells were transfected with
equal amounts of pNL4-3 or point deletion mutant proviral DNA as indicated.
After 48 h, equal volumes of supernatant from each culture were collected and
subjected to ultracentrifugation to pellet virus particles. Virus from each of these
point deletion mutants, in parallel with the parental NL4-3, was analyzed by
SDS-PAGE andWestern blot as described in Materials and methods. Full-length
Gag precursor (p55), CA-SP1 intermediate (p25), and mature CA (p24) are
indicated by arrows. The data presented in this figure are representative of at
least three independent experiments.A particularly interesting result was that the majority of the
SP1 point deletion mutants displayed a normal or near normal
Gag processing phenotype with the near normal phenotype
characterized by a slight accumulation of Gag processing
intermediates such as P41Gag (Fig. 4). It should also be noted
that while mutants with deletions at I376 or M377 (residues
flanking the SP1-NC cleavage site) not unexpectedly exhibited
an SP1-NC cleavage defect as evidenced by the significant
accumulation of Western blot bands corresponding in size to
CA-SP1-NC-SP2 and CA-SP1-NC (Fig. 4), CA-SP1 cleavage
did not appear to be affected. Our results indicate that deletion
of any single residue within SP1, with the exception of the 1st
residue (A364), does not appear to disrupt CA-SP1 processing,
or significantly affect virus production in the context of the
HeLa cell transfections. Due to the effect of point deletions
within the C-terminal domain of CA or at the N-terminus of SP1
on virus particle production or Gag processing, virus incorpor-
ating these changes could not be used in assays to characterize
the determinants of PA-457 activity.
Replication properties of non-defective CA-SP1 point deletion
variants
To determine the replication properties of the non-defective
CA-SP1 point deletion constructs, equal quantities of the
respective proviral DNAs were transfected into Jurkat cells,
and virus replication was monitored by regular measurements of
extracellular p24 over a 21-day post-transfection period. The
data in Fig. 5 show that these point deletion mutants exhibit one
of three replication phenotypes; (i) fully competent (akin to the
parental NL4-3), (ii) intermediate, and (iii) defective. Fully
replication-competent phenotypes included mutants with a
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downstream from the CA-SP1 cleavage site. Mutants containing
a deletion at residues S368, Q369, or I376 exhibited reduced
replication kinetics and were classified as replication-intermedi-
ate. In contrast to these first two groups, viruses containing a
deletion at any of the CA-SP1 cleavage-site-proximal residues
(E365/A366/M367), or with a deletion at the C-terminus of the SP1Fig. 4. Western blot analysis of the effect of PA-457 at 1 μg/ml on the conversion
of the capsid precursor, CA-SP1, to mature capsid protein (A–C). The virus for
Western blotting was obtained using a constant volume of cell culture
supernatant. This resulted in some variability in the intensity of the viral
protein bands due to differences among the point deletion mutants in the level of
virus production. Gag precursor (p55), the Gag intermediates (CA-SP1-NC or
CA-SP1-NC-SP1), the CA-SP1 intermediate (p25), and mature CA (p24) are
indicated by arrows. The data presented in this figure are representative of at
least four independent experiments. Additional experiments for mutant viruses
ΔA366 andΔM367 in which the amount of Gag protein loaded onto the gel was
normalized to the NL4-3 control gave identical results to those presented above
(data not shown).
Fig. 5. Replication kinetics of the parental NL4-3 and single residue point
deletion mutant viruses in Jurkat cells. Jurkat cells were transfected with equal
amounts of the parental pNL4-3 or single residue point deletion mutant proviral
DNA and cultured for 3 weeks. Viral replication was monitored regularly by p24
antigen capture ELISA. The data presented in this figure are representative of at
least three independent experiments.domain (M377), produced only background levels of extra-
cellular p24, indicating a lack of viral replication during the 21-
day observation period.
We next determined the extent to which the replication
phenotypes observed with this panel of point deletion variants
correlated with viral particle production. Interestingly, we did
not observe a strict correlation between replication competence
and virus production. This conclusion assumes that the HeLa
cells utilized in the experiment represented in Fig. 2 and the
Jurkat cells used to generate data shown in Fig. 5 behave
similarly with respect to the replication of these mutant viruses.
For example, the ΔS368 mutant produced an approximately
equal amount of virus as mutants ΔP373 and ΔA374; however,
ΔS368 exhibited an intermediate replication phenotype whereas
ΔP373 andΔA374 replicated as well as the parental NL4-3. From
this, we conclude that the observed variations in viral particle
production do not fully explain the replication phenotypes.
Rather, these results suggested that viruses produced by the
replication-defective mutants (ΔE365, ΔA366, ΔM367 and
ΔM377) were non-infectious while viral particles derived from
the replication-intermediate mutants (ΔS368, ΔQ369 and ΔI376)
were attenuated and less infectious. Mechanisms by which the
introduced changes impact virus infectivity warrant further
investigation.
Sensitivity of Gag SP1 point deletion constructs to PA-457
The non-defective Gag SP1 point deletion mutants were
characterized for sensitivity to PA-457 in studies that measured
the effect of the compound on p25 processing (CA-SP1
cleavage). In these experiments, HeLa cells were transfected
in parallel with the parental NL4-3 or SP1 variant proviral DNA
in the presence of PA-457 at a concentration of 1 μg/ml or
DMSO control. At 48 h post-transfection, virus was harvested
from the cell culture supernatant and the Gag processing profile
for each virus was analyzed and compared to Gag processing in
the absence of compound (DMSO control) (Fig. 4).
As summarized in Fig. 4, these experiments revealed a
striking difference in compound sensitivity among the point
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with residue E365 and extending through V370 yielded a PA-
457-resistant phenotype as evidenced by a lack of accumulation
of the CA-SP1 precursor (p25) in the presence of compound.
These data indicate that the N-terminal residues of SP1 are
required for PA-457 activity. The observation of a critical role
for residue A366 in the compound's antiviral activity is
consistent with previous resistance selection experiments that
identified both A364 and A366 as determinants of PA-457
activity (Li et al., 2003; unpublished results). In contrast to these
PA-457-resistant variants, viruses with a deletion at any position
starting with residue T371 through I376 were sensitive to PA-457
treatment, as evidenced by the significant accumulation of the
CA precursor, p25. These results demonstrate that the majority
of residues within the C-terminus of Gag SP1 do not play a
direct role in the activity of PA-457. Compared to the entire
panel of PA-457-sensitive mutants, ΔT371 was unique in that it
exhibited intermediate sensitivity to compound treatment. We
speculate that this intermediate PA-457-sensitive phenotype,
identifies the T371 residue as transition point within SP1 from
the region critical to PA-457 activity to the region not directly
involved in the activity of the compound.
As noted previously, deletion of either the I376 or M377
residue resulted in a clear Gag processing defect in the absence
of PA-457. We speculate that this effect on processing results
from the critical position of these two residues in flanking the
SP1-NC cleavage site. Interestingly, ΔI376 was sensitive to PA-
457 treatment while ΔM377 was not.
The Gag processing experiments specifically measure the
effect of PA-457 on CA-SP1 cleavage and the ability of the
compound to inhibit the release of mature CA protein. To
further characterize the effect of PA-457 on virus replication in
the panel of SP1 point deletion mutants, we employed the U87
CD4/CXCR4 cell-based replication assay. As summarized in
Table 1, the results of this assay correlate well with thoseTable 1
Summary of the effect of point deletions on PA-457 activity
Virus Gag processing assay Cell-based replication assay
NL4-3 + a +
ΔE365 − b NAc
ΔA366 − NA
ΔM367 − NA
ΔS368 − −
ΔQ369 − −
ΔV370 − −
ΔT371 + +
ΔN372 + +
ΔP373 + +
ΔA374 + +
ΔT375 + +
ΔI376 + NA
ΔM377 − NA
a Full PA-457 activity as determined in Gag processing experiment or in cell-
based replication assay.
b A lack of PA-457 activity as determined in Gag processing experiment or in
cell-based replication assay.
c Data could not be generated due to replication defects of these mutants in
U87 CD4 CXCR4 cells.obtained in the Gag processing experiment. For example,
parental level PA-457 inhibitory activity was consistently
observed in the panel of mutants including ΔT371, ΔN372,
ΔP373, ΔA374, and ΔT375, which exhibited PA-457 sensitivity
in the Gag processing experiment. Additionally, three point
deletion mutants (ΔS368, ΔQ369, and ΔV370) identified as PA-
457-resistant in the Gag processing experiment lacked com-
pound sensitivity in the virus replication assay. Together, these
results demonstrate a strong correlation between the cell-based
replication assay and the Gag processing experiment in
characterizing PA-457 activity against HIV-1. These data
further support observations regarding the critical role of the
N-terminal half of SP1 in PA-457 activity.
Discussion
PA-457 is a potent HIV drug candidate that acts through a
novel mechanism of action to block Gag processing and inhibit
virus replication (Li et al., 2003; Zhou et al., 2004b). The
primary goal of the work described in this report was to extend
our understanding of the viral determinants of PA-457 activity.
We chose the CA-SP1 cleavage domain as our main focus
because: (i) PA-457 inhibits virus replication by blocking Gag
cleavage at this site and (ii) several residues proximal to the CA-
SP1 cleavage site have previously been shown to play
significant roles in mediating resistance to PA-457(Li et al.,
2003; Zhou et al., 2004a, 2004b).
Our experiments generated a number of new observations
with respect to the viral determinants of PA-457 activity.
Significantly, the determinants of compound activity mapped to
a relatively large region of the Gag SP1 domain with each
residue within the N-terminal half of SP1 being required for PA-
457 activity (Fig. 4 and Table 1). Not unexpectedly, the entire
C-terminal half of the SP1 domain, with the exception of
residue M377, was not implicated in PA-457 activity (Fig. 4 and
Table 1). Surprisingly, the M377 residue, furthest removed from
the CA-SP1 cleavage site, in some as yet to be determined
fashion, affects PA-457 activity. We believe that there are
several possible explanations for this latter observation. One
possibility involves the effect of the M377 deletion on the rate of
CA-SP1 cleavage. It has been shown that the rate of CA-SP1
processing is regulated by cleavage at the SP1-NC site with a
block to processing at that site resulting in a 20-fold increase in
the rate of CA-SP1 cleavage (Pettit et al., 1994). It has also been
demonstrated that an M to I substitution at P1 of the SP1-NC
cleavage site significantly reduces the level of processing at that
site (Pettit et al., 2002). We speculate that the increase in the rate
of CA-SP1 processing resulting from the M377 deletion
(equivalent to an M to I substitution at P1) could affect the
ability of PA-457 to disrupt this cleavage event resulting in the
PA-457-resistant phenotype. Consistent with this hypothesis,
Sakalian et al. (2006) recently described one example of a
mutation-induced increase in the rate of CA-SP1 processing that
seemed to correlate with a reduction in PA-457 activity. An
alternative explanation involves the direct interaction of the
M377 residue with PA-457 and the effect of the deletion of this
residue on PA-457 binding and activity. However, as reported
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Zhou et al., 2004a, 2004b), viral determinants of PA-457
activity, mapped by several different approaches, cluster to the
region flanking the CA-SP1 cleavage site. To date, distal site
effects on compound activity have not been reported.
Additionally, changing the M377 residue to either A or L
resulted in a PA-457-sensitive phenotype (unpublished results);
strongly suggesting that M377 is not directly involved in the
interaction with PA-457. A final possible explanation involves
the contribution of the M377 residue to the formation of
necessary PA-457 target structures. We speculate that the
deletion of the M377 residue could disrupt PA-457 target
formation resulting in the observed drug-resistant phenotype.
A lack of functional mutant viruses impeded our efforts to
better understand the role of the C-terminal residues of CA in
PA-457 sensitivity. However, based on our observations in
characterizing the role of the SP1 residues, we would predict
that a relatively large number of C-terminal CA residues
proximal to the CA-SP1 cleavage site are involved in compound
activity. Results from our efforts to select for and characterize
PA-457-resistant isolates support this hypothesis. Our most
recent in vitro drug-resistance selection studies have identified a
number of C-terminal CA residues that confer some level of PA-
457 resistance. These include the last residue of capsid, CAL231
as well as the sixth capsid residue upstream from the CA-SP1
cleavage site, CAH226 (unpublished results). We believe that it is
likely that these residues play a critical role in mediating the
effect of the compound on CA-SP1 processing. To obtain
additional information, several other approaches, including the
preparation of SIV/HIV Gag CA-SP1 chimeras and an
alternative mutagenesis approach involving site-specific sub-
stitutions targeting the C-terminus of CA are being pursued in
our laboratories.
It should be noted that the Gag residues identified in this
study as viral determinants of PA-457 activity overlap a region
of the protein predicted to exhibit α-helical secondary structure
(Accola et al., 1998; Morellet et al., 2005). It has been proposed
that this putative helical structure plays an important role in
HIV-1 assembly and budding based on the observation that the
introduction of structure-disrupting mutations into this region of
Gag results in a defect in virus particle production (Accola et al.,
1998; Liang et al., 2002). While the determinants of PA-457
activity map to this putative structural domain, we and others
have shown that the compound exhibits no discernible effect on
virus assembly and budding (Li et al., 2003; Zhou et al., 2004b).
A possible explanation for this observation involves a
mechanism by which PA-457 binds to the CA-SP1 region of
Gag and disrupts p25 processing without interfering with the
function of the putative structural elements. A more complete
understanding of the structure and function of this region of Gag
in HIV-1 morphogenesis and the mechanism of PA-457 action
will be required before more definitive conclusions can be
drawn.
The model by which PA-457 exerts its antiviral activity has
been proposed in earlier reports in which we speculated that PA-
457 bound directly to the CA-SP1 cleavage site in the context of
a higher-order Gag structure and disrupted p25 processing byblocking PR access to this site. The results reported here are
consistent with this model, and extend our characterization of
the PA-457 target to include portions of the CA-SP1 cleavage
domain other than the residues immediately flanking the p25
cleavage site. Although our results do not completely rule out
other potential PA-457 targets, such as an unidentified cellular
factor necessary for Gag processing, we believe the proposed
model is most consistent with the previous results reported by
our group and others (Li et al., 2003; Sakalian et al., 2006; Zhou
et al., 2004a, 2004b, 2005). Ongoing studies to identify and
characterize a direct binding site for PA-457 should allow for a
more definitive identification of the molecular target for this
novel compound and provide a more complete evaluation of our
proposed model for PA-457 action.
Materials and methods
Construction of HIV-1 NL4-3 point deletion mutants
To map the genetic determinants of PA-457 activity, we
generated a panel of single residue point deletion mutants
spanning the CA-SP1 cleavage domain in the context of the
HIV-1 NL4-3 molecular clone (obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID). The CA-SP1 sequences for these constructs are shown
in Fig. 1 and the numbering of CA-SP1 residues is based on the
standard nomenclature system for the Gag polyprotein of the
HXB2 virus (Kuiken et al., 2000). DNA mutagenesis was
carried out using the PCR–ligation–PCR strategy and other
standard molecular cloning techniques as previously described
(Ho et al., 1989; Sambrook et al., 1989). Each clone was
analyzed to confirm the sequence of the Gag CA-SP1 region.
Cell culture, DNA transfection and infection
HeLa cells were maintained in DMEM (Invitrogen) supple-
mented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml
Streptomycin, and cells were passaged upon confluence. Jurkat
E6-1 cells (obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID) were
cultured in RPMI 1640 medium (Meditech) supplemented with
10%FBS, and 50 μg/ml of gentamicin (Sigma). Jurkat cells were
passaged every 2–3 days to maintain a concentration of 105–106
cells/ml. All plasmid DNAs were prepared using the Qiagen
midiprep kit.
HeLa and Jurkat cells were transiently transfected with equal
amounts of parental or mutant NL4-3 proviral DNAs using the
FuGENE 6 transfection reagent (Roche). HeLa cells were
employed to address the effect of the point deletions on virus
production and Gag processing. At 48 h post-transfection, both
cells and culture supernatant were harvested for analysis (see
SDS-PAGE and Western blot sections below). p24 antigen
capture ELISA (ZeptoMetrix) was used to measure the level
of virus production from HeLa cell transfection. The effect of
point deletions on virus replication kinetics was characterized
in Jurkat cells where virus replication was monitored by regular
measurements of extracellular p24 protein over a 21-day
223F. Li et al. / Virology 356 (2006) 217–224observation period post-transfection, as described previously
(Demirov et al., 2002b).
SDS-PAGE and Western blot
Western blotting was used to characterize the effect of the
point deletions on virus production and Gag polyprotein
processing. Briefly, at 48 h post-transfection, culture medium
containing viral particles was collected and clarified by
centrifugation at 4 °C for 20 min at 2000 rpm using a Sorvall
RT 6000B centrifuge. Virus-containing supernatants were then
concentrated through a 20% sucrose cushion in a microcen-
trifuge at 4 °C for 120 min at 13,000 rpm and pellets were
resuspended in lysis buffer (150 mM Tris–HCl, 5% Triton X-
100, 1% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), pH
8.0). For analysis of cell lysates, at 48 h post-transfection, cells
were washed once with PBS, lysed, and then centrifuged at 4 °C
for 5 min at 13,000 rpm to remove nuclear fractions. Viral
proteins were separated on a 12% NuPAGE Bis-Tris Gel
(Invitrogen) and transferred to a nitrocellulose membrane
(Invitrogen) followed by blocking in a PBS buffer containing
0.5% Tween and 5% dry milk powder. The membrane was
incubated with pooled immunoglobulin from HIV-1-infected
patients (HIV-Ig) (obtained through the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID)
and hybridized with goat anti-human horseradish peroxidase
(Sigma). The immune complex was visualized using an ECL
system (Amersham Pharmacia Biotech) according to the
instructions provided by the manufacturer.
Effect of PA-457 on Gag processing in point deletion mutants
To address the effect of the point deletions on the ability of
PA-457 to inhibit CA-SP1 processing, HeLa cells were
transfected with parental HIV-1 pNL4-3 and various point
deletion mutant proviral DNAs as described above. PA-457 at a
concentration of 1 μg/ml or DMSO (no drug control) was
maintained throughout the entire period of the culture and SDS-
PAGE/Western blot for analyzing viral proteins derived from
these cultures was performed as described above.
In vitro cell-based antiviral activity assay
PA-457 was tested for in vitro activity against the point
deletion mutations using U87.CD4/CXCR4 cells as targets.
Cells were plated in a 96-well flat-bottom plate at a 3×103 cells/
well one-day prior to use. PA-457 was tested in triplicate at a
starting concentration of 0.1 μg/ml, followed by three 10-fold
serial dilutions. Next, virus stocks generated by HeLa cell
transfections were added to each well. Virus inocula ranged
from 25 to 250 TCID50/ml. Cultures were maintained on days 1,
3, and 6 post-infection. Maintenance consisted of removing
spent medium from each well and adding an equal volume of
fresh medium. On days 6 and 8 post-infection, culture
supernatant was collected for p24 ELISA analysis according
to the manufacture's instructions (ZeptoMetrix). Linear regres-
sion was used to determine EC50 values.Acknowledgments
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